Needham & Company Downgrades Vertex (VRTX) to Hold
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- Wall Street ends lower on semiconductor selloff as AI spending concerns mount
- Chip stocks plunge, but bargain-hunters stem losses in other tech names
- FedEx falls 4% as FY2027 profit forecast misses expectations despite Q4 beat
- Oil prices finish 1% lower as investors focus on Hormuz flows after peace talks
- South Korea leveraged ETF crisis sparks global chip selloff
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Needham Starts NeoVolta (NEOV) at Buy
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
Maxim Group Downgrades Vertex (VRTX) to Hold
January 29, 2015 7:30 AM ESTMaxim Group downgraded Vertex (NASDAQ: VRTX) from Buy to Hold with a price target of $121.00 (from $148.00).
Analyst Jason Kolbert commented:
Vertex reported YE2014 non-GAAP revenue and operating expenses of $536M and $920M, respectively, and a non-GAAP loss of $511M and EPS of ($2.17). Revenue was driven largely by Kalydeco sales of $464M. Vertex enters 2015 with... MoreVertex Pharma (VRTX) Posts Smaller Q4 Loss
January 28, 2015 4:11 PM ESTVertex Pharma (NASDAQ: VRTX) reported Q4 EPS of ($0.55), $0.10 better than the analyst estimate of ($0.65). Revenue for the quarter came in at $145 million versus the consensus estimate of $137.5 million.
"The potential approval and launch of the combination of lumacaftor and ivacaftor and continued label... More
